2010-02-03 13:42:19 -

Rosetta Genomics (NASDAQ:ROSG) today announced that the United States Patent and Trademark Office (USPTO) has issued three patents to the company covering the composition of matter of human microRNAs.

The first (U.S. Patent No. 7,655,785) relates to human miR-527; the second (U.S. Patent No. 7,642,348) relates to human miR-491 and the third (U.S. Patent No. 7,618,814) relates to human miR-135b.

Human miR-527, has recently been shown to be a predictor of progesterone receptor status in breast cancer. Human miR-491 has been shown to be involved in colorectal cancer and liver necrosis. Human miR-135b is highly expressed in colon cancer specimens relative to normal colon tissues.

Rosetta now has six issued patents and 11 allowed patent applications covering composition of matter of microRNAs in

humans.

“With these three new patents, along with the two allowed patent applications we announced last week and further applications already filed, we are assembling an intellectual property estate that we believe keeps us at the forefront of microRNA research while providing protection for a growing portfolio of diagnostic tests,” said Kenneth A.

Berlin, president and chief executive officer.

Rosetta Genomics has filed more than 35 patent applications in the U.S.

and more than 36 patent applications worldwide to protect each aspect of its commercial diagnostic products. Many of these applications protect the specific microRNAs used in the company’s products. In addition, the company is pursuing more than 50 patent applications to protect methods of detecting microRNAs and methods of diagnosing and treating diseases with microRNAs.



About Rosetta Genomics

Rosetta Genomics is a leading developer of microRNA-based molecular diagnostics. Founded in 2000 the company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic tools. The company’s first three microRNA-based tests, miRview™ squamous, miRview™ mets and miRview™ meso, are commercially available through its Philadelphia-based CLIA-certified lab. Rosetta Genomics is the 2008 winner of The Wall Street Journal’s Technology Innovation Awards in the medical/biotech category. To learn more, please visit www.rosettagenomics.com : .


Forward-Looking Statements

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to Rosetta’s intellectual property and patent coverage and advancement of Rosetta’s pipeline of products, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2008 on file with the Securities and Exchange Commission.
In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.



Company Contact:Rosetta GenomicsRon Kamienchick,

215-382-9000 x 318 investors@rosettagenomics.com : mailto:investors@rosettagenomics.com orInvestor
Contacts:Lippert/Heilshorn & AssociatesKim Sutton

Golodetz, 212-738-3777 kgolodetz@lhai.com : mailto:kgolodetz@lhai.com orBruce
Voss, 310-691-7100 bvoss@lhai.com : mailto:bvoss@lhai.com